<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744677</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT02744677</nct_id>
  </id_info>
  <brief_title>COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction</brief_title>
  <official_title>COngenital Multicenter Trial of Pulmonic vAlve Dysfunction Studying the SAPIEN 3 interventIONal THV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3&#xD;
      Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular&#xD;
      outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a&#xD;
      clinical indication for intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2016</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>THV dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as a non-hierarchical composite of: RVOT reintervention, Moderate or greater total pulmonary regurgitation (PR) via Transthoracic Echocardiography (TTE), Mean RVOT gradient &gt; 40 mmHg via TTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Discharge, expected to be within 1-5 days post-procedure</time_frame>
    <description>Defined as a composite of: 1) Single THV implanted in the desired location, 2) RV-PA peak-to-peak gradient &lt; 35 mmHg post-implantation, 3) Less than moderate PR by discharge TTE (or earliest evaluable TTE), 4) Free of explant at 24 hours post-implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RVOT gradient</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paravalvular and total PR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RVOT reintervention</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery compression requiring intervention</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THV frame fracture</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related endocarditis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause, procedural and device-related)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Complex Congenital Heart Defect</condition>
  <condition>Dysfunctional RVOT Conduit</condition>
  <condition>Pulmonary Valve Insufficiency</condition>
  <condition>Pulmonary Valve Degeneration</condition>
  <arm_group>
    <arm_group_label>TPVR - Main Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPVR - THV Registry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3 THV</intervention_name>
    <description>SAPIEN 3 THV in the pulmonic position</description>
    <arm_group_label>TPVR - Main Cohort</arm_group_label>
    <arm_group_label>TPVR - THV Registry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Weight ≥ 20 kg (44 lbs.)&#xD;
&#xD;
          2. Dysfunctional RVOT conduit or previously implanted valve in the pulmonic position with&#xD;
             a clinical indication for intervention and with a landing zone diameter ≥ 16.5 mm and&#xD;
             ≤ 29 mm immediately prior to study device insertion as per the Instructions for Use&#xD;
&#xD;
          3. Subject presents with at least moderate PR and/or mean RVOT gradient ≥ 35 mmHg.&#xD;
&#xD;
          4. The subject/subject's legally authorized representative has been informed of the&#xD;
             nature of the study, agrees to its provisions and has provided written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection requiring current antibiotic therapy (if temporary illness, subject&#xD;
             may be a candidate 2 weeks after discontinuation of antibiotics)&#xD;
&#xD;
          2. History of or active endocarditis (active treatment with antibiotics) within the past&#xD;
             180 days&#xD;
&#xD;
          3. Leukopenia, anemia, thrombocytopenia or any known blood clotting disorder&#xD;
&#xD;
          4. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN 3 THV&#xD;
&#xD;
          5. Need for concomitant atrial septal defect or ventricular septal defect closure or&#xD;
             other concomitant interventional procedures other than pulmonary artery or branch&#xD;
             pulmonary artery stenting or angioplasty&#xD;
&#xD;
          6. Angiographic evidence of coronary artery compression that would result from&#xD;
             transcatheter pulmonic valve implantation (TPVI)&#xD;
&#xD;
          7. Emergency interventional/surgical procedures within 30 days prior to the TPVI&#xD;
             procedure.&#xD;
&#xD;
          8. Any planned surgical, percutaneous coronary or peripheral procedure to be performed&#xD;
             within the 30 day follow-up from the TPVI procedure.&#xD;
&#xD;
          9. History of or current intravenous drug use&#xD;
&#xD;
         10. Major or progressive non-cardiac disease resulting in a life expectancy of less than&#xD;
             one year&#xD;
&#xD;
         11. Known hypersensitivity to aspirin or heparin and cannot be treated with other&#xD;
             antiplatelet and/or antithrombotic medications&#xD;
&#xD;
         12. Known hypersensitivity to cobalt-chromium, nickel or contrast media that cannot be&#xD;
             adequately premedicated&#xD;
&#xD;
         13. Currently participating in an investigational drug or another device study.&#xD;
&#xD;
         14. Positive urine or serum pregnancy test in female subjects of child-bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Scott Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasilis Babaliaros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwards THV Clinical Affairs</last_name>
    <phone>(949) 250-2500</phone>
    <email>THV_CT.gov@Edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California,, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University/Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University Barnes- Jewish Medical/ St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York - Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center, University of Pennsylvania/ Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart Institute (IMC)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia (UVA)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetralogy of Fallot</keyword>
  <keyword>Aortic Valve Defect/Disease Resulting in Ross Procedure</keyword>
  <keyword>Pulmonary Atresia</keyword>
  <keyword>Pulmonary Stenosis</keyword>
  <keyword>Truncus Arteriosus</keyword>
  <keyword>Transposition of the Great Arteries</keyword>
  <keyword>Transcatheter pulmonary valve implantation</keyword>
  <keyword>Transcatheter pulmonary valve replacement</keyword>
  <keyword>TPV</keyword>
  <keyword>TPVR</keyword>
  <keyword>TPVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

